Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010 - PubMed (original) (raw)
. 2007 May;100(5):277-89.
doi: 10.1093/qjmed/hcm020. Epub 2007 Apr 21.
Affiliations
- PMID: 17449875
- DOI: 10.1093/qjmed/hcm020
Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010
D Fidan et al. QJM. 2007 May.
Abstract
Background: Coronary heart disease (CHD) in the UK affects approximately 3 million people, with >100,000 deaths annually. Mortality rates have halved since the 1980s, but annual NHS treatment costs for CHD exceed 2 billion pounds.
Aim: To examine the cost-effectiveness of specific CHD treatments in England and Wales.
Methods: The IMPACT CHD model was used to calculate the number of life-years gained (LYG) from specific cardiological interventions from 2000 to 2010. Cost-effectiveness ratios (costs per LYG) were generated for each specific intervention, stratified by age and sex. The robustness of the results was tested using sensitivity analyses.
Results: In 2000, medical and surgical treatments together prevented or postponed approximately 25,888 deaths in CHD patients aged 25-84 years, thus generating approximately 194,929 extra life-years between 2000 and 2010 (range 143,131-260,167). Aspirin and beta-blockers for secondary prevention following myocardial infarction or revascularisation, for angina and heart failure were highly cost-effective (< 1000 pounds per LYG). Other secondary prevention therapies, including cardiac rehabilitation, ACE inhibitors and statins, were reasonably cost-effective (1957 pounds, 3398 pounds and 4246 pounds per LYG, respectively), as were CABG surgery (3239 pounds-4601 pounds per LYG) and angioplasty (3845 pounds-5889 pounds per LYG). Primary angioplasty for myocardial infarction was intermediate (6054 pounds-12,057 pounds per LYG, according to age), and statins in primary prevention were much less cost-effective (27,828 pounds per LYG, reaching 69,373 pounds per LYG in men aged 35-44). Results were relatively consistent across a wide range of sensitivity analyses.
Discussion: The cost-effectiveness ratios for standard CHD treatments varied by over 100-fold. Large amounts of NHS funding are being spent on relatively less cost-effective interventions, such as statins for primary prevention, angioplasty and CABG surgery. This merits debate.
Similar articles
- The population mortality benefits of maximizing the number of eligible patients receiving appropriate cardiology treatments in Ireland.
Kabir Z, Bennett K, Shelley E, Unal B, Critchley J, Feely J, Capewell S. Kabir Z, et al. QJM. 2006 Aug;99(8):523-30. doi: 10.1093/qjmed/hcl072. Epub 2006 Jul 22. QJM. 2006. PMID: 16861717 - Quality of care for secondary prevention for patients with coronary heart disease: results of the Hastening the Effective Application of Research through Technology (HEART) trial.
Goff DC Jr, Gu L, Cantley LK, Sheedy DJ, Cohen SJ. Goff DC Jr, et al. Am Heart J. 2003 Dec;146(6):1045-51. doi: 10.1016/S0002-8703(03)00522-2. Am Heart J. 2003. PMID: 14660997 Clinical Trial. - Cost effectiveness of statins in coronary heart disease.
Franco OH, Peeters A, Looman CW, Bonneux L. Franco OH, et al. J Epidemiol Community Health. 2005 Nov;59(11):927-33. doi: 10.1136/jech.2005.034900. J Epidemiol Community Health. 2005. PMID: 16234419 Free PMC article. Review. - Secondary prevention of coronary heart disease in the elderly.
Dornbrook-Lavender KA, Roth MT, Pieper JA. Dornbrook-Lavender KA, et al. Ann Pharmacother. 2003 Dec;37(12):1867-76. doi: 10.1345/aph.1D026. Ann Pharmacother. 2003. PMID: 14632542 Review.
Cited by
- Prevention of postoperative pulmonary complications through preoperative physiotherapy interventions in patients undergoing coronary artery bypass graft: literature review.
Perelló-Díez M, Paz-Lourido B. Perelló-Díez M, et al. J Phys Ther Sci. 2018 Aug;30(8):1034-1038. doi: 10.1589/jpts.30.1034. Epub 2018 Jul 24. J Phys Ther Sci. 2018. PMID: 30154596 Free PMC article. Review. - Inequalities in access to cardiac rehabilitation after an acute coronary syndrome: the EPiHeart cohort.
Viana M, Borges A, Araújo C, Rocha A, Ribeiro AI, Laszczyńska O, Dias P, Maciel MJ, Moreira I, Lunet N, Azevedo A. Viana M, et al. BMJ Open. 2018 Jan 3;8(1):e018934. doi: 10.1136/bmjopen-2017-018934. BMJ Open. 2018. PMID: 29301762 Free PMC article. - A cost effectiveness analysis of salt reduction policies to reduce coronary heart disease in four Eastern Mediterranean countries.
Mason H, Shoaibi A, Ghandour R, O'Flaherty M, Capewell S, Khatib R, Jabr S, Unal B, Sözmen K, Arfa C, Aissi W, Ben Romdhane H, Fouad F, Al-Ali R, Husseini A; MedCHAMPS project team. Mason H, et al. PLoS One. 2014 Jan 7;9(1):e84445. doi: 10.1371/journal.pone.0084445. eCollection 2014. PLoS One. 2014. PMID: 24409297 Free PMC article. - Aerobic exercise-based cardiac rehabilitation in Chinese patients with coronary heart disease: study protocol for a pilot randomized controlled trial.
Cao RY, Zheng H, Mi Q, Li Q, Yuan W, Ding Y, Yang J. Cao RY, et al. Trials. 2018 Jul 9;19(1):363. doi: 10.1186/s13063-018-2771-8. Trials. 2018. PMID: 29986745 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous